Journal Article

Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice

Bellut, Maximilian, Weber, Alexander N. R., Schuhmann, Michael K., Bieber, Michael, Kraft, Peter, Stoll, Guido

2023

Overview

Background Ischemic stroke immediately evokes a strong neuro-inflammatory response within the vascular compartment, which contributes to primary infarct development under vessel occlusion as well as further infarct growth despite recanalization, referred to as ischemia/reperfusion injury. Later, in the subacute phase of stroke (beyond day 1 after recanalization), further inflammatory processes within the brain parenchyma follow. Whether this second wave of parenchymal inflammation contributes to an additional/secondary increase in infarct volumes and bears the potential to be pharmacologically targeted remains elusive. We addressed the role of the NLR-family pyrin domain-containing protein 3 (NLRP3) inflammasome in the subacute phase of ischemic stroke. Methods Focal cerebral ischemia was induced in C57Bl/6 mice by a 30-min transient middle cerebral artery occlusion (tMCAO). Animals were treated with the NLRP3 inhibitor MCC950 therapeutically 24 h after or prophylactically before tMCAO. Stroke outcome, including infarct size and functional deficits as well as the local inflammatory response, was assessed on day 7 after tMCAO. Results Infarct sizes on day 7 after tMCAO decreased about 35% after delayed and about 60% after prophylactic NLRP3 inhibition compared to vehicle. Functionally, pharmacological inhibition of NLRP3 mitigated the local inflammatory response in the ischemic brain as indicated by reduction of infiltrating immune cells and reactive astrogliosis. Conclusions Our results demonstrate that the NLRP3 inflammasome continues to drive neuroinflammation within the subacute stroke phase. NLRP3 inflammasome inhibition leads to a better long-term outcome—even when administered with a delay of 1 day after stroke induction, indicating ongoing inflammation-driven infarct progression. These findings may pave the way for eagerly awaited delayed treatment options in ischemic stroke.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Animals / Biomedical and Life Sciences / Biomedicine / Brain Ischemia - metabolism / Care and treatment / Cerebral ischemia / Complications and side effects / Development and progression / Immunology / Infarction, Middle Cerebral Artery - complications / Infarction, Middle Cerebral Artery - drug therapy / Infarction, Middle Cerebral Artery - metabolism / Inflammasome / Inflammasomes - antagonists & inhibitors / Inflammasomes - metabolism / Inflammation - complications / Ischemic stroke / Ischemic Stroke - complications / Ischemic Stroke - drug therapy / Mice / Mice, Inbred C57BL / Middle cerebral artery occlusion / Neurobiology / Neuroinflammation / Neurology / Neurosciences / NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors / NLR Family, Pyrin Domain-Containing 3 Protein - metabolism / NLRP3 / Reperfusion Injury - metabolism / Secondary infarct growth / Stroke (Disease) / Stroke - metabolism